Hepatic Encephalopathy Clinical Trial
Official title:
Impact of Coenzyme Q10 and Meclofenoxate on Frequency and Severity of Hepatic Encephalopathy
Hepatic encephalopathy is a syndrome occurs in patients with liver cirrhosis and is defined
as neuropsychiatric abnormalities in patients with liver impairment, characterized by
personality changes, intellectual impairment, and an impaired level of consciousness.
Coenzyme Q10 (CoQ10) is a necessary cofactor of the mitochondrial metabolism. It provides a
High antioxidant and protective effects on age-related morbidities such as hypertension,
heart failure and neurodegenerative diseases and hepatoprotective effects in drug related
hepatic impairment.
Meclofenoxate is a cholinergic nootropic drug used clinically to improve memory, mental
function and general cognition.
Hepatic encephalopathy is a syndrome occurs in patients with liver cirrhosis and is defined
as neuropsychiatric abnormalities in patients with liver impairment, characterized by
personality changes, intellectual impairment, and an impaired level of consciousness. Hepatic
encephalopathy is categorized into Type A hepatic encephalopathy associated with acute liver
failure; Type B hepatic encephalopathy is associated with portal-systemic bypass and no
intrinsic hepatocellular disease; Type C hepatic encephalopathy describes encephalopathy
associated with Cirrhosis and portal hypertension; type C hepatic encephalopathy is, in turn,
subcategorized as episodic, persistent, or minimal.
A number of theories had been postulated, it was proposed that hepatic encephalopathy is a
disorder of astrocyte function which play a key role in the regulation of the blood-brain
barrier, maintaining electrolyte homeostasis , a role in the detoxification of chemicals,
including ammonia.
neurotoxic substances, including ammonia and manganese cause morphologic changes in the
astrocytes leading to Alzheimer type II astrocytosis in cirrhosis.
Hepatic encephalopathy may be due to accumulated neurotoxic substances in the brain as
short-chain fatty acids; mercaptans; false neurotransmitters, such as tyramine, octopamine,
and beta-phenylethanolamines; manganese; ammonia; and gamma-aminobutyric acid (GABA).
Coenzyme Q10 (CoQ10) is a necessary cofactor of the mitochondrial metabolism. It provides a
High antioxidant and protective effects on age-related morbidities such as hypertension,
heart failure and neurodegenerative diseases and hepatoprotective effects in drug related
hepatic impairment.
Meclofenoxate is a cholinergic nootropic drug used clinically to improve memory, mental
function and general cognition.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01559519 -
Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy
|
Phase 4 | |
| Terminated |
NCT01846806 -
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
|
N/A | |
| Recruiting |
NCT01178372 -
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis
|
Phase 4 | |
| Completed |
NCT00914056 -
A Study of Controlled Lactulose Withdrawal
|
N/A | |
| Completed |
NCT00740142 -
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
|
Phase 4 | |
| Completed |
NCT00558038 -
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
|
Phase 2 | |
| Completed |
NCT00986895 -
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
|
Phase 1 | |
| Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
| Recruiting |
NCT05539027 -
Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy
|
Phase 4 | |
| Recruiting |
NCT04096014 -
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
|
N/A | |
| Completed |
NCT05526404 -
Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
|
N/A | |
| Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
| Enrolling by invitation |
NCT06367127 -
Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
|
||
| Active, not recruiting |
NCT05425316 -
Speech in Hepatic Encephalopathy (HE)
|
||
| Recruiting |
NCT04415294 -
Flicker App for Minimal Hepatic Encephalopathy
|
||
| Not yet recruiting |
NCT06072521 -
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
|
Phase 2 | |
| Completed |
NCT02636647 -
Fecal Transplant in Recurrent Hepatic Encephalopathy
|
Phase 1 | |
| Withdrawn |
NCT02086825 -
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
|
Phase 3 | |
| Completed |
NCT01446523 -
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
|
N/A | |
| Completed |
NCT01218568 -
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial
|
N/A |